{
  "description": "FDA-approved drug-disease pairs identified during validation. These should be added to ground truth to improve evaluation accuracy.",
  "last_updated": "2026-01-25",
  "pairs": [
    {
      "drug": "Pembrolizumab",
      "disease": "Triple-negative breast cancer",
      "fda_approval_year": 2020,
      "notes": "KEYNOTE-355 (metastatic), KEYNOTE-522 (early-stage)",
      "added_to_gt": "2026-01-25",
      "gt_entries": [
        "triple-negative breast carcinoma",
        "invasive breast carcinoma",
        "breast cancer",
        "breast carcinoma"
      ]
    },
    {
      "drug": "Pembrolizumab",
      "disease": "Breast cancer",
      "fda_approval_year": 2021,
      "notes": "High-risk early-stage TNBC",
      "added_to_gt": "2026-01-25",
      "gt_entries": [
        "triple-negative breast carcinoma",
        "invasive breast carcinoma",
        "breast cancer",
        "breast carcinoma"
      ]
    },
    {
      "drug": "Doxorubicin",
      "disease": "Breast cancer",
      "fda_approval_year": 1974,
      "notes": "Anthracycline chemotherapy, cornerstone treatment"
    },
    {
      "drug": "Methotrexate",
      "disease": "Breast cancer",
      "fda_approval_year": 1959,
      "notes": "Part of CMF regimen"
    },
    {
      "drug": "Natalizumab",
      "disease": "Multiple sclerosis",
      "fda_approval_year": 2004,
      "notes": "Tysabri, first mAb for MS"
    },
    {
      "drug": "Erlotinib",
      "disease": "Pancreatic cancer",
      "fda_approval_year": 2005,
      "notes": "Tarceva + gemcitabine"
    },
    {
      "drug": "Cetuximab",
      "disease": "Colorectal cancer",
      "fda_approval_year": 2004,
      "notes": "Erbitux, KRAS wild-type"
    },
    {
      "drug": "Oxaliplatin",
      "disease": "Colorectal cancer",
      "fda_approval_year": 2002,
      "notes": "FOLFOX regimen"
    },
    {
      "drug": "Bevacizumab",
      "disease": "Colorectal cancer",
      "fda_approval_year": 2004,
      "notes": "Avastin, anti-VEGF"
    },
    {
      "drug": "Trametinib",
      "disease": "Melanoma",
      "fda_approval_year": 2013,
      "notes": "Mekinist, BRAF V600E/K"
    },
    {
      "drug": "Prednisone",
      "disease": "Rheumatoid arthritis",
      "fda_approval_year": 2012,
      "notes": "RAYOS delayed-release"
    },
    {
      "drug": "Umeclidinium",
      "disease": "COPD",
      "fda_approval_year": 2014,
      "notes": "Incruse Ellipta, also in Trelegy"
    },
    {
      "drug": "Thiotepa",
      "disease": "Cancer",
      "fda_approval_year": 1959,
      "notes": "Alkylating agent, various cancers"
    },
    {
      "drug": "Ustekinumab",
      "disease": "Ulcerative colitis",
      "fda_approval_year": 2019,
      "notes": "UNIFI Phase 3 trial",
      "added_to_gt": "2026-01-25"
    },
    {
      "drug": "Ustekinumab",
      "disease": "Psoriasis",
      "fda_approval_year": 2009,
      "notes": "First IL-12/23 inhibitor for psoriasis",
      "added_to_gt": "2026-01-25"
    },
    {
      "drug": "Guselkumab",
      "disease": "Ulcerative colitis",
      "fda_approval_year": 2024,
      "notes": "QUASAR Phase 3, first IL-23 for UC",
      "added_to_gt": "2026-01-25"
    },
    {
      "drug": "Doxorubicin",
      "disease": "choriocarcinoma",
      "notes": "h593 GT gap auto-detection",
      "added_to_gt": "2026-02-06",
      "gt_entries": [
        "choriocarcinoma"
      ]
    },
    {
      "drug": "Paclitaxel",
      "disease": "germ cell testicular cancer",
      "notes": "h593 GT gap auto-detection",
      "added_to_gt": "2026-02-06",
      "gt_entries": [
        "germ cell testicular cancer"
      ]
    },
    {
      "drug": "Fluorouracil",
      "disease": "tongue cancer",
      "notes": "h593 GT gap auto-detection",
      "added_to_gt": "2026-02-06",
      "gt_entries": [
        "tongue cancer"
      ]
    },
    {
      "drug": "Verapamil",
      "disease": "acute coronary syndrome",
      "notes": "h593 GT gap auto-detection",
      "added_to_gt": "2026-02-06",
      "gt_entries": [
        "acute coronary syndrome"
      ]
    },
    {
      "drug": "Posaconazole",
      "disease": "cryptococcal meningitis",
      "notes": "h593 GT gap auto-detection",
      "added_to_gt": "2026-02-06",
      "gt_entries": [
        "cryptococcal meningitis"
      ]
    },
    {
      "drug": "Posaconazole",
      "disease": "chromomycosis",
      "notes": "h593 GT gap auto-detection",
      "added_to_gt": "2026-02-06",
      "gt_entries": [
        "chromomycosis"
      ]
    },
    {
      "drug": "Posaconazole",
      "disease": "ringworm tinea corporis",
      "notes": "h593 GT gap auto-detection",
      "added_to_gt": "2026-02-06",
      "gt_entries": [
        "ringworm tinea corporis"
      ]
    },
    {
      "drug": "Posaconazole",
      "disease": "cryptococcosis",
      "notes": "h593 GT gap auto-detection",
      "added_to_gt": "2026-02-06",
      "gt_entries": [
        "cryptococcosis"
      ]
    },
    {
      "drug": "Posaconazole",
      "disease": "cutaneous candidiasis",
      "notes": "h593 GT gap auto-detection",
      "added_to_gt": "2026-02-06",
      "gt_entries": [
        "cutaneous candidiasis"
      ]
    },
    {
      "drug": "Voriconazole",
      "disease": "cutaneous candidiasis",
      "notes": "h596 triazole antifungal GT expansion: Triazole for candida, FDA class",
      "added_to_gt": "2026-02-06",
      "gt_entries": [
        "cutaneous candidiasis"
      ]
    },
    {
      "drug": "Voriconazole",
      "disease": "chronic mucocutaneous candidiasis",
      "notes": "h596 triazole antifungal GT expansion: Triazole for candida",
      "added_to_gt": "2026-02-06",
      "gt_entries": [
        "chronic mucocutaneous candidiasis"
      ]
    },
    {
      "drug": "Voriconazole",
      "disease": "cryptococcosis",
      "notes": "h596 triazole antifungal GT expansion: IDSA alternative for fluconazole-intolerant",
      "added_to_gt": "2026-02-06",
      "gt_entries": [
        "cryptococcosis"
      ]
    },
    {
      "drug": "Isavuconazonium",
      "disease": "zygomycosis/mucormycosis",
      "notes": "h596 triazole antifungal GT expansion: FDA primary indication",
      "added_to_gt": "2026-02-06",
      "gt_entries": [
        "zygomycosis/mucormycosis"
      ]
    }
  ],
  "mesh_mappings_to_add": [
    {
      "drug": "Pembrolizumab",
      "drugbank_id": "DB09037",
      "disease_mesh": "D001943"
    },
    {
      "drug": "Doxorubicin",
      "drugbank_id": "DB00997",
      "disease_mesh": "D001943"
    },
    {
      "drug": "Methotrexate",
      "drugbank_id": "DB00563",
      "disease_mesh": "D001943"
    },
    {
      "drug": "Natalizumab",
      "drugbank_id": "DB00108",
      "disease_mesh": "D009103"
    },
    {
      "drug": "Erlotinib",
      "drugbank_id": "DB00530",
      "disease_mesh": "D010190"
    },
    {
      "drug": "Cetuximab",
      "drugbank_id": "DB00002",
      "disease_mesh": "D015179"
    },
    {
      "drug": "Oxaliplatin",
      "drugbank_id": "DB00526",
      "disease_mesh": "D015179"
    },
    {
      "drug": "Bevacizumab",
      "drugbank_id": "DB00112",
      "disease_mesh": "D015179"
    },
    {
      "drug": "Trametinib",
      "drugbank_id": "DB08911",
      "disease_mesh": "D008545"
    },
    {
      "drug": "Umeclidinium",
      "drugbank_id": "DB09076",
      "disease_mesh": "D029424"
    }
  ]
}